enGene Therapeutics Announces Name Change Ahead of Potential 2027 Approval

Name change reflects company's transition towards commercialization of lead bladder cancer therapy detalimogene.

Apr. 7, 2026 at 2:41pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph of the intricate internal structure of a human bladder, with glowing, ghostly lines defining the organ's complex anatomy against a dark background, conceptually representing a new therapeutic approach for bladder cancer.enGene's novel gene therapy detalimogene aims to offer a new treatment option for bladder cancer patients with limited alternatives.Boston Today

enGene Therapeutics Inc. (formerly enGene Holdings Inc.) announced it will change its corporate name to 'enGene Therapeutics Inc.' effective April 8, 2026. The name change reflects the company's near-term transition to a commercial organization with the potential approval of its lead therapy detalimogene for high-risk non-muscle invasive bladder cancer (NMIBC) in 2027.

Why it matters

The name change signals enGene's progress in advancing detalimogene, a novel non-viral gene therapy, through late-stage clinical trials. If approved, detalimogene could provide a much-needed new treatment option for NMIBC patients who are unresponsive to the current standard of care, Bacillus Calmette-Guérin (BCG) therapy.

The details

Detalimogene is being evaluated in the ongoing LEGEND Phase 2 trial, including a pivotal cohort studying the therapy in high-risk, BCG-unresponsive NMIBC patients with carcinoma in situ (CIS), with or without concomitant papillary disease. enGene plans to submit a Biologics License Application (BLA) for detalimogene in the second half of 2026 based on data from this pivotal cohort.

  • The name change will take effect on April 8, 2026.
  • enGene plans to submit a BLA for detalimogene in the second half of 2026.

The players

enGene Therapeutics Inc.

A clinical-stage biotechnology company developing non-viral gene therapies, including the lead program detalimogene for non-muscle invasive bladder cancer.

Ron Cooper

President and Chief Executive Officer of enGene Therapeutics Inc.

Got photos? Submit your photos here. ›

What they’re saying

“We're entering an important next phase for enGene as we prepare for potential approval of detalimogene in 2027. Our new name reflects our progress — and the opportunity to bring detalimogene to patients and the practices that care for them, where more options are still needed.”

— Ron Cooper, President and Chief Executive Officer

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This name change highlights enGene's advancement towards potentially bringing a much-needed new therapy option to NMIBC patients who have limited treatment choices, especially those unresponsive to the current standard of care.